What makes a biotech investable in 2026?
At UK Biotech Day 2025, tranScrip hosted a roundtable discussion bringing together biotech founders, pharmaceutical leaders and development experts to explore perceptions of how investor expectations are evolving and what characteristics might increasingly define investable biotech companies.
While scientific innovation remains fundamental, the discussion highlighted a clear shift towards execution, capital efficiency and strategic planning.
- Investability now extends far beyond great science
Scientific innovation remains the foundation of biotech value creation, but investors are increasingly looking beyond the asset itself. Development strategy, leadership capability, execution plans and a clear route to value creation are becoming equally important components of the investment story.
- Capital efficiency has become a defining factor
Investors are paying closer attention to how companies deploy resources and achieve milestones. Lean operating models, strategic partnerships, outsourcing and virtual biotech structures are increasingly viewed as effective ways to maximise capital and reduce development risk.
- Clinical validation is becoming increasingly important
While strong science remains essential, participants noted that investors are placing greater emphasis on programmes that have begun to demonstrate clinical relevance and a credible pathway to value creation.
- The funding environment has become more selective, not necessarily worse
Capital remains available, but investors are applying greater scrutiny and conducting deeper diligence. Companies that demonstrate strong differentiation, realistic development plans and disciplined execution continue to attract interest.
- Innovation remains critical, but risk aversion is shaping investment decisions
While breakthrough science remains essential, there was broad agreement that investors and larger pharmaceutical companies are increasingly favouring validated mechanisms, later-stage assets, and lower-risk opportunities.
Looking Ahead
Strong science remains necessary, but it is no longer sufficient. In today’s funding environment, the most investable biotech companies combine differentiated innovation with disciplined execution, capital efficiency and a credible strategy for creating value.
Download our full report for a deeper exploration of the themes shaping biotech investment in 2026.
